Discussion Referencs:

Ali, S. H. B., Bangash, K. S., Rauf, A., Younis, M., Anwar, K., Khurram, R., ... &
Qamar, R. (2017). Identification of novel potential genetic predictors of urothelial
bladder carcinoma susceptibility in Pakistani population. Familial cancer, 16(4), 577-
594.

Banerjee, R., Liu, M., Bellile, E., Schmitd, L. B., Goto, M., Hutchinson, M. K. N., ...
& D’Silva, N. J. (2022). Phosphorylation of TRIP13 at Y56 induces radiation
resistance but sensitizes head and neck cancer to cetuximab. Molecular
Therapy, 30(1), 468-484.

Chen, C., He, W., Huang, J., Wang, B., Li, H., Cai, Q., ... & Lin, T. (2018). LNMAT1
promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage
recruitment. Nature communications, 9(1), 1-18.

Dai, C., Zhang, Y., & Zhou, L. (2021). Expression of TRIP13, ZEB1, and E-cad in
Infiltrating Urothelial Carcinoma of Bladder and Their Clinical Significance.

DeSantis, C. E., Miller, K. D., Dale, W., Mohile, S. G., Cohen, H. J., Leach, C. R., ...
& Siegel, R. L. (2019). Cancer statistics for adults aged 85 years and older, 2019. CA:
a cancer journal for clinicians, 69(6), 452-467.

Dong, L., Ding, H., Li, Y., Xue, D., Li, Z., Liu, Y., ... & Wang, P. (2019). TRIP13 is a
predictor for poor prognosis and regulates cell proliferation, migration and invasion in
prostate cancer. International journal of biological macromolecules, 121, 200-206.

Fekry, M. F., ElRehim, D. M., Elghany, M. I., & Moussa, R. A. (2019).

Clinicopathologic significance of SOX2 protein expression in bladder
carcinoma. Egyptian Journal of Pathology, 39(2), 364.

Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros,
M., ... & Bray, F. (2019). Estimating the global cancer incidence and mortality in
2018: GLOBOCAN sources and methods. International journal of cancer, 144(8),
1941-1953.
Gao, Y., Liu, S., Guo, Q., Zhang, S., Zhao, Y., Wang, H., ... & Wang, Z. (2019).
Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in
association with the EGFR signaling pathway. International Journal of Biological
Sciences, 15(7), 1488.

Gayyed, M. F., & Tawfiek, E. R. (2015). Utility of SOX2 and livin co-expression in
the prognosis of bladder cancer with bilharzial and non-bilharzial bladder
status. World journal of oncology, 6(5), 446.

Hu, L., Shen, D., Liang, D., Shi, J., Song, C., Jiang, K., ... & Meng, S. (2020).
Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop
promoting glioblastoma growth. Cancer Letters, 493, 156-166.

Khaled, H. M. (2005). Systemic management of bladder cancer in Egypt:

revisited. Journal of the Egyptian National Cancer Institute, 17(3), 127-131.

Li, W., Zhang, G., Li, X., Wang, X., Li, Q., Hong, L., ... & Zhou, J. (2018). Thyroid
hormone receptor interactor 13 (TRIP13) overexpression associated with tumor
progression and poor prognosis in lung adenocarcinoma. Biochemical and biophysical
research communications, 499(3), 416-424.

Lopez‐Beltran, A., Henriques, V., Montironi, R., Cimadamore, A., Raspollini, M. R.,
& Cheng, L. (2019). Variants and new entities of bladder
cancer. Histopathology, 74(1), 77-96.

Lu, S., Guo, M., Fan, Z., Chen, Y., Shi, X., Gu, C., & Yang, Y. (2019). Elevated
TRIP13 drives cell proliferation and drug resistance in bladder cancer. American
Journal of Translational Research, 11(7), 4397.

Magers, M. J., Lopez‐Beltran, A., Montironi, R., Williamson, S. R., Kaimakliotis, H.

Z., & Cheng, L. (2019). Staging of bladder cancer. Histopathology, 74(1), 112-134.

Marks, D. H., Thomas, R., Chin, Y., Shah, R., Khoo, C., & Benezra, R. (2017). Mad2
overexpression uncovers a critical role for TRIP13 in mitotic exit. Cell reports, 19(9),
1832-1845.
Moussa, R. A., & Ali, A. I. (2019). Prognostic role of epithelial-mesenchymal
transition markers “E-cadherin, β-catenin, ZEB1, ZEB2 and p63” in bladder
carcinoma. World Journal of Oncology, 10(6), 199.

Nagy, A. A., Darweish, H., Hamdey, H. M., Elkalla, R., & Abdu-allah, H. (2018).
Factors Affecting Survival in Egyptian Patients Suffering from Urinary Bladder
Cancer: A Multicenter Retrospective Study. J Cancer Sci Ther, 10, 031-035.

Niu, L., Gao, Z., Cui, Y., Yang, X., & Li, H. (2019). Thyroid receptor-interacting
protein 13 is correlated with progression and poor prognosis in bladder
cancer. Medical Science Monitor: International Medical Journal of Experimental and
Clinical Research, 25, 6660.

Qian, B., Ying, X., Yang, G., Li, H., & Tan, J. (2021). TRIP13 is identified as a
prognosis biomarker for renal clear cell carcinoma and promotes renal cell carcinoma
cell proliferation, migration and invasion. Biocell, 45(3), 577.

Salem, H. K., & Mahfouz, S. (2012). Changing patterns (age, incidence, and
pathologic types) of schistosoma-associated bladder cancer in Egypt in the past
decade. Urology, 79(2), 379-383.

Salem, H. K., & Mahfouz, S. (2012). Changing patterns (age, incidence, and
pathologic types) of schistosoma-associated bladder cancer in Egypt in the past
decade. Urology, 79(2), 379-383.

Sheng, N., Yan, L., Wu, K., You, W., Gong, J., Hu, L., ... & Wang, Z. (2018).
TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal
cancer. Cell death & disease, 9(3), 1-14.

Stec, R., Cierniak, S., Lubas, A., Brzóskowska, U., Syryło, T., Zieliński, H., &
Semeniuk-Wojtaś, A. (2020). Intensity of nuclear staining for Ki-67, p53 and survivin
as a new prognostic factor in non-muscle invasive bladder cancer. Pathology &
Oncology Research, 26(2), 1211-1219.

Teoh, J. Y. C., Huang, J., Ko, W. Y. K., Lok, V., Choi, P., Ng, C. F., ... & Wong, M.
C. S. (2020). Global trends of bladder cancer incidence and mortality, and their
associations with tobacco use and gross domestic product per capita. European
urology, 78(6), 893-906.

Zhou, X. Y., & Shu, X. M. (2019). TRIP13 promotes proliferation and invasion of
epithelial ovarian cancer cells through Notch signaling pathway. Eur Rev Med
Pharmacol Sci, 23(2), 522-529.